5 August 2026

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400001,
Maharashtra, India

Scrip Code: 540975

The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai 400051,
Maharashtra, India

Scrip Symbol: ASTERDM

Dear Sir/Madam,

Subject: **Outcome of the Board Meeting - Unaudited Financial Results (standalone and consolidated) for the first quarter ended 30 June 2026**

Ref: **Regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")**

With reference to our letter dated 30 July 2026 and in accordance with Regulation 30 and 33 of the Listing Regulations, we wish to inform you that the Board of Directors of Aster DM Quality Care Limited (formerly known as Aster DM Healthcare Limited) ("the Board" and "the Company", respectively) at its meeting held today i.e. 5 August 2026, *inter alia*, has approved the unaudited financial results (standalone and consolidated) of the Company for the quarter ended 30 June 2026 ("UFRs"), as reviewed and recommended by the Audit Committee. A copy of UFRs, along with the limited review report thereon issued by M/s. Deloitte Haskins & Sells, Statutory Auditors are enclosed. The UFRs shall be published in the newspapers as required under the Listing Regulations.

The Meeting of the Board of Directors commenced at 11:30 AM (IST) and concluded at 04:40 PM (IST).

The above information will also be hosted on the website of the Company i.e. www.asterqualitycare.com

This is for your information and records.

Thanking you,

For **Aster DM Quality Care Limited**
(Formerly known as Aster DM Healthcare Limited)

HEMISH PURUSHOTTAM
Digitally signed by HEMISH PURUSHOTTAM
Date: 2026.08.05 17:11:41 +05'30'

Hemish Purushottam
Company Secretary and Compliance Officer
M. No. A24331

Deloitte Haskins & Sells

Chartered Accountants
Prestige Trade Tower, Level 19
46, Palace Road, High Grounds
Bengaluru – 560 001
Karnataka, India

Tel: +91 80 6188 6000
Fax: +91 80 6188 6011

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ASTER DM QUALITY CARE LIMITED (formerly known as ASTER DM HEALTHCARE LIMITED)

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **ASTER DM QUALITY CARE LIMITED (formerly known as ASTER DM HEALTHCARE LIMITED)** ("the Company"), which includes interim financial information of DM Healthcare Employees Welfare Trust (the "ESOP trust") for the quarter ended 30 June 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listings Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Deloitte
Haskins & Sells

5. The Unaudited Standalone Financial Results includes the interim financial information of the ESOP trust which have not been reviewed by its auditor whose interim financial information reflect total revenue of INR 0.56 crores, total net profit after tax of INR 0.42 crores and total comprehensive income of INR 0.42 crores for the quarter ended 30 June 2026, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Company.

   Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For Deloitte Haskins & Sells
Chartered Accountants
(Firm's Registration No. 008072S)

ANKIT DAGA
Digitally signed by ANKIT DAGA
Date: 2026.08.05 16:29:57 +05'30'

Ankit Daga
(Partner)
(Membership No. 512486)
(UDIN: 26512486AFXMIV2992)

Place: Bengaluru
Date: 5 August 2026

Aster DM Quality Care Limited
(Formerly known as Aster DM Healthcare Limited)
CIN : L85110TS2008PLC207383
Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2026

(Amount in INR crores)

	Particulars	Quarter ended			Year ended
		30 June 2026	31 March 2026 (refer Note 9)	30 June 2025	31 March 2026
		(Unaudited)			(Audited)
1	**Income**				
	Revenue from operations	725.73	655.10	613.04	2,615.70
	Other income	39.03	40.55	38.43	155.03
	Total income	**764.76**	**695.65**	**651.47**	**2,770.73**
2	**Expenses**				
	Purchase of medicines and medical consumables	162.04	122.14	130.46	530.68
	Changes in inventories	(12.28)	8.15	(0.56)	8.49
	Professional fees to consultant doctors	165.48	149.99	136.22	579.85
	Laboratory outsourcing charges	21.91	18.98	17.92	78.55
	Employee benefits expense	121.39	103.94	91.48	403.45
	Finance costs	24.02	20.98	21.64	87.27
	Depreciation and amortisation expenses	41.32	37.57	37.88	154.02
	Other expenses	120.20	113.53	104.01	464.30
	Total expenses	**644.08**	**575.28**	**539.05**	**2,306.61**
3	**Profit before exceptional items and tax (1-2)**	**120.68**	**120.37**	**112.42**	**464.12**
4	**Exceptional items (refer Note 7)**	(109.79)	(77.73)	(4.39)	(89.92)
5	**Profit before tax (3+4)**	**10.89**	**42.64**	**108.03**	**374.20**
6	**Tax expenses**				
	Current tax	35.12	19.93	28.87	124.37
	Deferred tax	(9.93)	(4.75)	(1.43)	(17.99)
	Total tax expense	**25.19**	**15.18**	**27.44**	**106.38**
7	**Profit/(Loss) for the period / year (5-6)**	**(14.30)**	**27.46**	**80.59**	**267.82**
8	**Other comprehensive income/(loss) for the period / year**				
	Items that will not be reclassified subsequently to profit or loss				
	Remeasurement of net defined benefit liability	-	1.18	-	(0.21)
	Income tax relating to items that will not be reclassified to profit or loss	-	(0.30)	-	0.05
	Other comprehensive income/(loss), net of taxes	**-**	**0.88**	**-**	**(0.16)**
9	**Total comprehensive income/(loss) (7+8)**	**(14.30)**	**28.34**	**80.59**	**267.66**
10	Paid-up equity share capital (Face value of INR 10 each)	518.13	518.13	518.13	518.13
11	Other equity				3,848.09
12	Earnings/(Loss) per share (Face value of INR 10 each)	Not annualised	Not annualised	Not annualised	Annualised
	Basic (in INR)	(0.28)	0.53	1.58	5.20
	Diluted (in INR)	(0.28)	0.53	1.57	5.19

See accompanying notes to the Statement of Unaudited Standalone Financial Results

Aster DM Quality Care Limited
(Formerly known as Aster DM Healthcare Limited)
CIN : L85110TS2008PLC207383
Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Notes to the Statement of Unaudited Standalone Financial Results:

1) The Statement of Unaudited Standalone Financial Results of Aster DM Quality Care Limited ('the Company'), which includes the financial information of DM Healthcare Employees Welfare Trust (the 'ESOP Trust'), for the quarter ended 30 June 2026 ('the Statement') has been reviewed by the Audit Committee and approved by the Board of Directors on 05 August 2026. The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company, who have expressed an unmodified review conclusion.

2) The Statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

3) On 11 December 2025, the Company had submitted the Scheme of Amalgamation ('Scheme') by way of merger of Quality Care India Limited (Transferor Company/QCIL) with Aster DM Healthcare Limited (Transferee Company) (the 'Applicant Companies') to the National Company Law Tribunal ('NCLT') for approval of the said Scheme. Subsequently, on 19 June 2026, the NCLT has sanctioned the Scheme. On 26 June 2026, the Applicant Companies filed e-Form INC-28 with the Registrar of Companies, Telangana. Upon such filing and completion of all other conditions precedent as mentioned in the Scheme, the Scheme became effective on 01 July 2026, being the first day of the calendar month immediately following the month in which all such conditions are fulfilled. As per the terms of the Scheme, the name of the Company has been changed from "Aster DM Healthcare Limited" to "Aster DM Quality Care Limited".

4) The Company acquired additional 1.54% stake in its subsidiary Malabar Institute of Medical Sciences Limited, from several minority shareholders during the period 1 April 2026 to 30 June 2026 for an amount of INR 31.40 crores. Consequent to the said acquisition, shareholding of the Company in Malabar Institute of Medical Sciences Limited has increased from 79.75% as at 31 March 2026 to 81.29% as at 30 June 2026.

5) On 18 June 2026, the Company has made an additional investment in equity shares amounting to INR 45.09 Crores in Aster DM-Super Specialty Hospital (Sarjapur) Private Limited, a wholly owned subsidiary of the Company.

6) On 29 June 2026, the Company has made an additional investment in Optionally Convertible Redeemable Preference Shares (OCRPS) amounting to INR 25.00 crores in Alfaone Medicals Private Limited, an associate of the Company.

7) During the quarter ended 30 June 2026, the Company has incurred expenses amounting to INR 109.79 crores towards professional fees and such other costs relating to the merger. The same has been presented as Exceptional Items in the Statement.

8) In accordance with Ind AS 108, Operating Segments, segment information has been provided in the Statement of Unaudited Consolidated Financial Results of the Company and therefore no separate disclosure on segment information is given in the Statement of Unaudited Standalone Financial Results.

9) The figures for the quarter ended 31 March 2026 are balancing figures between the audited figures in respect of year ended 31 March 2026 and the unaudited published figures in respect of nine months ended 31 December 2025, which was subjected to limited review by the statutory auditors.

10) Statement of Unaudited Standalone Financial Results are available for perusal at the website of the Company and the stock exchanges.

For and on behalf of the Board of Directors of
Aster DM Quality Care Limited
CIN : L85110TS2008PLC207383

VARUN
SHADILAL
KHANNA

Digitally signed by VARUN SHADILAL KHANNA
Date: 2026.08.05 16:24:46 +05'30'

Varun Khanna
Managing Director & Group Chief Executive Officer
DIN 03584124
Bengaluru
05 August 2026

Deloitte
Haskins & Sells

Chartered Accountants
Prestige Trade Tower, Level 19
46, Palace Road, High Grounds
Bengaluru – 560 001
Karnataka, India

Tel: +91 80 6188 6000
Fax: +91 80 6188 6011

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ASTER DM QUALITY CARE LIMITED (formerly known as ASTER DM HEALTHCARE LIMITED)

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **ASTER DM QUALITY CARE LIMITED (formerly known as ASTER DM HEALTHCARE LIMITED)** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss of its associates for the quarter ended 30 June 2026 ("the Statement") which includes the financial information of DM Healthcare Employees Welfare Trust (the "ESOP trust") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the entities as provided in Annexure 1.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The Unaudited Consolidated Financial Results includes the interim financial information of 16 subsidiaries and ESOP trust which have not been reviewed by their auditors, whose interim financial information reflect total revenue of INR 61.53 crores, total loss after tax of INR 4.41 crores and total comprehensive loss of INR 4.41 crores for the quarter ended 30 June 2026, as considered in the Statement. The Unaudited Consolidated Financial Results also include the Group's share of net profit after tax of INR 0.15 crores and total comprehensive income of INR 0.15 crores for the quarter ended 30 June 2026, as considered in the Statement, in respect of 2 associates based on their interim financial information which have not been reviewed by their auditors.

   According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

   Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm’s Registration No. 008072S)

ANKIT DAGA
Digitally signed by ANKIT DAGA
Date: 2026.08.05 16:34:40 +05'30'

Ankit Daga
Partner
(Membership No. 512486)
(UDIN:26512486CGUGXM8845)

Place: Bengaluru
Date: 5 August 2026

Deloitte
Haskins & Sells

Annexure 1 – List of entities included in the Unaudited Consolidated Financial Results

S.No	Entity	Relationship	Country of incorporation
1	Aster DM Quality Care Limited (formerly known as Aster DM Healthcare Limited)	Parent	India
2	DM Med City Hospitals (India) Private Limited	Wholly owned Subsidiary	India
3	Ambady Infrastructure Private Limited	Wholly owned Subsidiary	India
4	Aster DM Multispecialty Hospital Private Limited (formerly known as Aster DM Healthcare (Trivandrum) Private Limited)	Wholly owned Subsidiary	India
5	Sri Sainatha Multispeciality Hospitals Private Limited	Wholly owned Subsidiary	India
6	Aster Clinical Lab LLP	Wholly owned Subsidiary	India
7	Aster DM Super-Specialty Hospital (Sarjapur) Private Limited	Wholly owned Subsidiary (w.e.f. 21 July 2025)	India
8	Aster DM Super-Specialty Hospital Private Limited (formerly known as Aster DM Super-Specialty Hospitals (Yeswanthpur) Private Limited)	Wholly owned Subsidiary (w.e.f. 28 July 2025)	India
9	DM Healthcare Employees Welfare Trust	Trust	India
10	Affinity Holdings Private Limited	Wholly owned Subsidiary	Mauritius
11	Malabar Institute of Medical Sciences Limited	Subsidiary	India
12	Dr. Ramesh Cardiac and Multispeciality Hospitals Private Limited	Subsidiary	India
13	Prerana Hospital Limited	Subsidiary	India

14	Hindustan Pharma Distributors Private Limited	Subsidiary	India
15	EMED Human Resources India Private Limited	Step down Subsidiary	India
16	Ezhimala Infrastructure LLP	Step down Subsidiary	India
17	Warseps Healthcare LLP	Step down Subsidiary	India
18	Sanghamitra Hospitals Private Limited	Step down Subsidiary	India
19	Aster Ramesh Duhita LLP	Step down Subsidiary	India
20	Komali Fertility Centre LLP	Step down Subsidiary	India
21	Komali Fertility Centre LLP Ongole	Step down Subsidiary	India
22	Adiran IB Healthcare Private Limited	Step down Subsidiary	India
23	Cantown Infra Developers LLP	Step down Subsidiary	India
24	Aasraya Healthcare LLP	Step down Subsidiary	India
25	MIMS Infrastructure and Properties Private Limited	Associate	India
26	Mindriot Research and Innovation Foundation	Associate	India
27	Alfaone Medicals Private Limited	Associate	India
28	Alfaone Retail Pharmacies Private Limited	Associate	India

Aster DM Quality Care Limited
(Formerly known as Aster DM Healthcare Limited)
CIN : L85110TS2008PLC207383
Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2026

(Amount in INR crores)

	Particulars	Quarter ended			Year ended
		30 June 2026	31 March 2026 (Refer Note 8)	30 June 2025	31 March 2026
		(Unaudited)			(Audited)
1	**Income**				
	Revenue from operations	1,310.68	1,182.38	1,077.87	4,643.22
	Other income	37.03	36.20	33.18	125.60
	Total income	**1,347.71**	**1,218.58**	**1,111.05**	**4,768.82**
2	**Expenses**				
	Purchase of medicines and medical consumables	300.37	258.97	247.15	1,047.61
	Changes in inventories	(8.60)	4.19	(0.01)	1.18
	Professional fees to consultant doctors	295.14	264.66	239.70	1,031.87
	Laboratory outsourcing charges	9.22	5.35	7.76	27.52
	Employee benefits expense	242.20	219.99	194.81	848.09
	Finance costs	31.21	29.99	30.77	122.98
	Depreciation and amortisation expenses	69.29	67.24	63.22	264.25
	Other expenses	208.03	196.64	181.10	785.92
	Total expenses	**1,146.86**	**1,047.03**	**964.50**	**4,129.42**
3	**Profit before share of loss of equity accounted investees, exceptional items and tax (1-2)**	**200.85**	**171.55**	**146.55**	**639.40**
4	Share of loss of equity accounted investees	(8.39)	(8.53)	(5.72)	(37.00)
5	Exceptional items (Refer Note 6)	(114.38)	0.33	(4.39)	(32.71)
6	**Profit before tax (3+4+5)**	**78.08**	**163.35**	**136.44**	**569.69**
7	**Tax expense**				
	Current tax	56.98	36.37	43.98	186.03
	Deferred tax	(8.18)	(26.60)	(1.10)	(43.44)
	Total tax expense	**48.80**	**9.77**	**42.88**	**142.59**
8	**Profit for the period/ year (6-7)**	**29.28**	**153.58**	**93.56**	**427.10**
9	**Other comprehensive income/ (loss) for the period/ year**				
	Items that will not be reclassified subsequently to profit or loss				
	Remeasurement of net defined benefit liability	-	2.72	-	(0.22)
	Income tax on items that will not be reclassified subsequently to profit or loss	-	(0.65)	-	0.05
	Items that will be reclassified subsequently to profit or loss				
	Exchange difference in translating financial statements of foreign operations	0.14	0.73	(0.54)	0.73
	Income tax on items that will be reclassified subsequently to profit or loss	(0.04)	(0.20)	0.14	(0.20)
	Other comprehensive income/ (loss), net of taxes	**0.10**	**2.60**	**(0.40)**	**0.36**
10	**Total comprehensive income (8+9)**	**29.38**	**156.18**	**93.16**	**427.46**
11	**Profit attributable to :**				
	Owners of the Company	16.06	140.17	85.52	388.14
	Non-controlling interests	13.22	13.41	8.04	38.96
	Profit for the period/ year	**29.28**	**153.58**	**93.56**	**427.10**
12	**Other comprehensive income/ (loss) attributable to :**				
	Owners of the Company	0.10	2.39	(0.40)	0.38
	Non-controlling interests	-	0.21	-	(0.02)
	Other comprehensive income/ (loss) for the period/ year	**0.10**	**2.60**	**(0.40)**	**0.36**
13	**Total comprehensive income attributable to :**				
	Owners of the Company	16.16	142.56	85.12	388.52
	Non-controlling interests	13.22	13.62	8.04	38.94
	Total comprehensive income for the period/ year	**29.38**	**156.18**	**93.16**	**427.46**
14	Paid-up equity share capital (Face value of INR 10 each)	518.13	518.13	518.13	518.13
15	Other equity				4,057.73
16	Earnings per share (Face value of INR 10 each) from	Not annualised	Not annualised	Not annualised	Annualised
	Basic	0.31	2.72	1.67	7.53
	Diluted	0.31	2.71	1.67	7.52

See accompanying notes to the Statement of Unaudited Consolidated Financial Results

Aster DM Quality Care Limited
(Formerly known as Aster DM Healthcare Limited)
CIN : L85110TS2008PLC207383
Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Notes to the Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2026:

1) The Statement of Unaudited Consolidated Financial Results of Aster DM Quality Care Limited ('the Parent Company'/'Company') and its subsidiaries (together referred to as 'the Group'), DM Healthcare Employees Welfare Trust (the 'ESOP Trust') and its share of loss in associates for the quarter ended 30 June 2026 ('the Statement') has been reviewed by the Audit Committee and approved by the Board of Directors on 05 August 2026. The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Parent Company, who have expressed an unmodified review conclusion.

2) The Statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

3) On 11 December 2025, the Parent Company had submitted the Scheme of Amalgamation ('Scheme') by way of merger of Quality Care India Limited (Transferor Company/QCIL) with Aster DM Healthcare Limited (Transferee Company) (the 'Applicant Companies') to the National Company Law Tribunal ('NCLT') for approval of the said scheme. Subsequently, on 19 June 2026, the NCLT has sanctioned the scheme. On 26 June 2026, the Applicant Companies filed e-Form INC-28 with the Registrar of Companies, Telangana. Upon such filing and completion of all other conditions precedent as mentioned in the Scheme, the Scheme became effective on 01 July 2026, being the first day of the calendar month immediately following the month in which all such conditions are fulfilled. As per the terms of the Scheme, the name of the Parent Company has been changed from "Aster DM Healthcare Limited" to "Aster DM Quality Care Limited".

4) The Parent Company acquired additional 1.54% stake in its subsidiary Malabar Institute of Medical Sciences Limited, from several minority shareholders during the period 1 April 2026 to 30 June 2026 for an amount of INR 31.40 crores. Consequent to the said acquisition, shareholding of the Parent Company in Malabar Institute of Medical Sciences Limited has increased from 79.75% as at 31 March 2026 to 81.29% as at 30 June 2026.

5) On 29 June 2026, the Parent Company has made an additional investment in Optionally Convertible Redeemable Preference Shares (OCRPS) amounting to INR 25.00 crores in Alfaone Medicals Private Limited, an associate of the Parent Company.

6) During the quarter ended 30 June 2026, the Group has incurred INR 114.38 crores towards professional fees and such other costs relating to the merger. The same has been presented as Exceptional Items in the Consolidated Financial Results.

7) The Board of Directors of Aster DM Multispecialty Hospital Private Limited ('ADMPL'), a wholly owned subsidiary of the Parent Company, at its meeting held on 16 June, 2026, had allotted 2,140,000 fully paid-up Series A Compulsorily Convertible Preference Shares ('CCPS') of face value of INR 50/- each, and 1,840,000 partly paid-up Series B CCPS of face value INR 50/- each (paid-up amount INR 5/-), to certain identified investors, by way of private placement, for consideration, amounting to INR 11.62 crores on the terms and conditions as approved by the shareholders of ADMPL.

   The Board of Directors of Aster DM Super-Specialty Hospital (Sarjapur) Private Limited ('Sarjapur Entity'), a wholly owned subsidiary of the Parent Company, at its meeting held on 23 June, 2026, had allotted 12,00,000 fully paid-up Series A CCPS of face value of INR 50/- each, and 34,30,000 partly paid-up Series B CCPS of face value INR 50/- each (paid up amount INR 5/-), to certain identified investors, by way of private placement, for consideration, amounting to INR 7.72 crores on the terms and conditions as approved by the shareholders of Sarjapur Entity.

   The above items have been accounted as Equity in the Consolidated Financial Results.

8) The figures for the quarter ended 31 March 2026 are balancing figures between the audited figures in respect of year ended 31 March 2026 and the unaudited published figures in respect of nine months ended 31 December 2025, which was subjected to limited review by the statutory auditors.

Aster DM Quality Care Limited
(Formerly known as Aster DM Healthcare Limited)
CIN : L85110TS2008PLC207383
Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Notes to the Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2026 (continued)

9) Segment details of Unaudited Consolidated Financial Results for the quarter ended 30 June 2026

(Amount in INR crores)

	Particulars	Quarter ended			Year ended
		30 June 2026	31 March 2026 (Refer Note 8)	30 June 2025	31 March 2026
		(Unaudited)			(Audited)
1	**Segment revenue**				
	Hospitals & Clinics	1,277.63	1,152.56	1,042.68	4,506.39
	Labs	41.46	38.51	34.70	153.50
	Wholesale Pharmacies	30.43	19.77	29.57	108.32
	Others	1.56	5.17	3.29	14.79
	Total	**1,351.08**	**1,216.01**	**1,110.24**	**4,783.00**
	Less: Inter-segment revenue	40.40	33.63	32.37	139.79
	Revenue from operations	**1,310.68**	**1,182.38**	**1,077.87**	**4,643.21**
2	**Segment results before tax, exceptional items and finance cost**				
	Hospitals & Clinics	238.92	206.82	172.96	780.42
	Labs	2.92	3.98	0.98	14.84
	Wholesale Pharmacies	0.52	(0.36)	0.35	0.79
	Others	(0.61)	(1.09)	(5.75)	(17.00)
	Total	**241.75**	**209.35**	**168.54**	**779.05**
	Adjustment :				
	Finance cost	(31.21)	(29.99)	(30.77)	(122.98)
	Share of loss of equity accounted investees	(8.39)	(8.53)	(5.72)	(37.00)
	Other unallocable expenditure net of unallocable income (including adjustment of exceptional items)	(124.07)	(7.47)	4.39	(49.38)
	Profit before tax	**78.08**	**163.36**	**136.44**	**569.69**
3	**Segment assets**				
	Hospitals & Clinics	6,974.03	6,711.99	6,184.73	6,711.99
	Labs	85.35	83.34	55.99	83.34
	Wholesale Pharmacies	49.13	55.34	56.06	55.34
	Others	26.60	26.62	25.00	26.62
	Unallocated	1,066.33	1,234.67	1,465.98	1,234.67
	Total	**8,201.44**	**8,111.96**	**7,787.76**	**8,111.96**
4	**Segment liabilities**				
	Hospitals & Clinics	3,041.42	2,937.45	2,838.60	2,937.45
	Labs	59.77	59.51	70.12	59.51
	Wholesale Pharmacies	8.63	8.75	27.89	8.75
	Unallocated	237.02	272.55	150.95	272.55
	Total	**3,346.84**	**3,278.26**	**3,087.56**	**3,278.26**

Note - During the quarter ended 31 March 2026, the Group revised its operating segments to align with Chief Operating Decision Maker ('CODM') review. Clinics have been merged with Hospitals and Labs presented separately. Comparative figures have been reclassified accordingly.

10) Statements of Unaudited Standalone and Consolidated Financial Results are available for perusal at the website of the Parent Company and the stock exchanges.

For and on behalf of the Board of Directors of
Aster DM Quality Care Limited
CIN : L85110TS2008PLC207383

VARUN SHADILAL KHANNA
Digitally signed by VARUN SHADILAL KHANNA
Date: 2026.08.05 16:23:48 +05'30'

Varun Khanna
Managing Director & Group Chief Executive Officer
DIN 03584124
Bengaluru
05 August 2026

Aster DM Quality Care Limited
(Formerly known as Aster DM Healthcare Limited)
CIN : L85110TS2008PLC207383
Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Annexure A to statement of Unaudited Consolidated Financial Results for the quarter and year ended 30 June 2026

Sl No	Entity	Relationship	Country of incorporation
1	Aster DM Quality Care Limited (Formerly known as Aster DM Healthcare Limited)	Parent	India
2	DM Med City Hospitals (India) Private Limited	Wholly owned Subsidiary	India
3	Ambady Infrastructure Private Limited	Wholly owned Subsidiary	India
4	Aster DM Multispecialty Hospital Private Limited (formerly known as Aster DM Healthcare (Trivandrum) Private Limited)	Wholly owned Subsidiary	India
5	Sri Sainatha Multispeciality Hospitals Private Limited	Wholly owned Subsidiary	India
6	Aster Clinical Lab LLP	Wholly owned Subsidiary	India
7	Aster DM Super-Specialty Hospital (Sarjapur) Private Limited	Wholly owned Subsidiary (w.e.f. July 21, 2025)	India
8	Aster DM Super-Specialty Hospital (Yeswanthpur) Private Limited	Wholly owned Subsidiary (w.e.f. July 28, 2025)	India
9	DM Healthcare Employees Welfare Trust	Trust	India
10	Affinity Holdings Private Limited	Wholly owned Subsidiary	Mauritius
11	Malabar Institute of Medical Sciences Limited	Subsidiary	India
12	Dr. Ramesh Cardiac and Multispeciality Hospitals Private Limited	Subsidiary	India
13	Prerana Hospital Limited	Subsidiary	India
14	Hindustan Pharma Distributors Private Limited	Subsidiary	India
15	EMED Human Resources India Private Limited	Step down Subsidiary	India
16	Ezhimala Infrastructure LLP	Step down Subsidiary	India
17	Warseps Healthcare LLP	Step down Subsidiary	India
18	Sanghamitra Hospitals Private Limited	Step down Subsidiary	India
19	Aster Ramesh Duhita LLP	Step down Subsidiary	India
20	Komali Fertility Centre LLP	Step down Subsidiary	India
21	Komali Fertility Centre LLP Ongole	Step down Subsidiary	India
22	Adiran IB Healthcare Private Limited	Step down Subsidiary	India
23	Cantown Infra Developers LLP	Step down Subsidiary	India
24	Aasraya Healthcare LLP	Step down Subsidiary	India
25	MIMS Infrastructure and Properties Private Limited	Associate	India
26	Alfaone Medicals Private Limited	Associate	India
27	Alfaone Retail Pharmacies Private Limited	Associate	India
28	Mindriot Research and Innovation Foundation	Associate	India